

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Osteoporosis	Receptor activator of NF- κ B ligand (RANKL; TNFSF11)	Studies in cell culture identified benzopyranyl tetracycle-based inhibitors of osteoclastogenesis that could help treat osteoporosis. In two murine cell lines, the best inhibitor from the series decreased Rankl-induced osteoclastogenesis with single-digit micromolar IC ₅₀ values. Next steps include evaluating the inhibitor in animal models. Prolia denosumab, a human mAb targeting RANKL from Amgen Inc., Daiichi Sankyo Co. Ltd. and GlaxoSmithKline plc, is marketed to treat osteoporosis. SciBX 3(48); doi:10.1038/scibx.2010.1448 Published online Dec. 16, 2010	Patent application filed; available for licensing from the Seoul National University Research and Development Business Foundation	Zhu, M. <i>et al. J. Med. Chem.</i> ; published online Nov. 29, 2010; doi:10.1021/jm1011269 Contact: Seung Bum Park, Seoul National University, Seoul, South Korea e-mail: sbpark@snu.ac.kr Contact: Seong Hwan Kim, same affiliation as above e-mail: hwan@kriect.re.kr